HomeNDC LookupRxCUI directory › RxCUI 2564037

Belumosudil 200 MG Oral Tablet [Rezurock] — RxCUI 2564037

RxNorm drug concept · Semantic branded drug
RxCUI 2564037 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2564037
Official nameBelumosudil 200 MG Oral Tablet [Rezurock]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asRezurock 200 MG Oral Tablet; Rezurock 200 MG (as belumosudil mesylate 242.5 MG) Oral Tablet
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)979 prescriptions · 13 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Belumosudil: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Chronic GVHD (graft-versus-host disease) happens after a stem cell or bone marrow transplant, when the donor's immune cells treat your body as foreign and attack it. It can cause i...
  • What exactly is chronic GVHD, and why do I need this specific medication?
  • Yes, it really matters. Taking Rezurock with a meal roughly doubles the amount your body absorbs compared to taking it on an empty stomach. Always take it with food — and try to ta...
  • Does it matter if I take Rezurock with food or on an empty stomach?
📖 Read our full Belumosudil guide →

🕸️ Concept Web — How Belumosudil 200 MG Oral Tablet [Rezurock] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Belumosudil 200 MG Oral Tablet [Rezurock] RxCUI 2564037

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Belumosudil 2564025
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Rezurock 2564032
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Belumosudil Oral Tablet 2564030
    • Belumosudil Oral Product 2564028
    • Belumosudil Pill 2564029
    • Belumosudil Oral Tablet [Rezurock] 2564034
    • Rezurock Oral Product 2564035
    • Rezurock Pill 2564036
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Belumosudil 200 MG Oral Tablet SCD · 2564031
  • Belumosudil 200 MG SCDC · 2564027
  • Belumosudil Oral Tablet SCDF · 2564030
  • Belumosudil Oral Product SCDG · 2564028
  • Belumosudil Pill SCDG · 2564029

Brand-Name Concepts

  • Belumosudil 200 MG [Rezurock] SBDC · 2564033
  • Belumosudil Oral Tablet [Rezurock] SBDF · 2564034
  • Rezurock Oral Product SBDG · 2564035
  • Rezurock Pill SBDG · 2564036
  • Rezurock BN · 2564032

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2564037 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
79802-0200-30 1 BOTTLE in 1 CARTON (79802-200-30) / 30 TABLET in 1 BOTTLE Rezurock Kadmon Pharmaceuticals, LLC 2021-07-16
Observed labelers: Kadmon Pharmaceuticals, LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.